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Abstract
Nonalcoholic fatty liver disease (NAFLD) is highly prevalent and associated with considerable morbidities. Unfortunately,
there is no currently available drug established to treat NAFLD. It was recently reported that intraperitoneal administration
of taurine-conjugated ursodeoxycholic acid (TUDCA) improved hepatic steatosis in ob/ob mice. We hereby examined the
effect of oral TUDCA treatment on hepatic steatosis and associated changes in hepatic gene expression in ob/ob mice. We
administered TUDCA to ob/ob mice at a dose of 500 mg/kg twice a day by gastric gavage for 3 weeks. Body weight, glucose
homeostasis, endoplasmic reticulum (ER) stress, and hepatic gene expression were examined in comparison with control
ob/ob mice and normal littermate C57BL/6J mice. Compared to the control ob/ob mice, TUDCA treated ob/ob mice
revealed markedly reduced liver fat stained by oil red O (44.265.8% vs. 21.1610.4%, P,0.05), whereas there was no
difference in body weight, oral glucose tolerance, insulin sensitivity, and ER stress. Microarray analysis of hepatic gene
expression demonstrated that oral TUDCA treatment mainly decreased the expression of genes involved in de novo
lipogenesis among the components of lipid homeostasis. At pathway levels, oral TUDCA altered the genes regulating amino
acid, carbohydrate, and drug metabolism in addition to lipid metabolism. In summary, oral TUDCA treatment decreased
hepatic steatosis in ob/ob mice by cooperative regulation of multiple metabolic pathways, particularly by reducing the
expression of genes known to regulate de novo lipogenesis.
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Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most common
cause of chronic liver disease [1,2,3] and its prevalence ranges from
10–30% of the general population in the United States [1,3,4,5].
NAFLD includes a spectrum of liver diseases from simple hepatic
steatosis to nonalcoholic steatohepatitis (NASH) [1,3], where the
latter is known to increase the risk of liver cirrhosis and
hepatocellular carcinoma [6]. Insulin resistance and metabolic
syndrome are commonly associated with NAFLD and their
presence is a predictable factor of progressive liver dysfunction,
which may lead to hepatic failure [7]. The pathophysiology of
NAFLD is complex involving dietary factors, physical inactivity,
obesity, and genetic components [1,2,3].Although weightreduction
by lifestyle modification (i.e., caloric restriction and increased
physical activity) remains the most effective and desirable treatment
of NAFLD [1,8,9], long-term adherence to a new lifestyle is the
mainstayforsuccess[8],which ispracticallyverydifficulttoachieve.
Several agents are known to improve NAFLD histologically or
biochemically in animal models and humans [1,2,10,11,12,13].
Among them, ursodeoxycholic acid (UDCA), an endogenous bile
acid, improves liver function in patients with a wide range of
chronic liver diseases [14,15,16]. Furthermore, UDCA was
demonstrated to decrease liver enzyme levels and the degree of
steatosis in an open label pilot study [17]. However, in a
randomized placebo-controlled trial conducted in NASH patients,
UDCA revealed only comparable effects to the placebo in terms of
serum liver enzyme levels, hepatic steatosis, necroinflammation,
and fibrosis [12]. Taurine-conjugated UDCA (TUDCA) is more
hydrophilic and has a more obvious cytoprotective effect against
hepatocellular injury than UDCA [18,19,20]. It was reported that
intraperitoneally injected TUDCA improved hepatic steatosis in
ob/ob mice, which was associated with improvement of
endoplasmic reticulum (ER) stress in the liver [21]. In a very
recent study conducted in obese human subjects focused on tissue
insulin sensitivity [22], oral TUDCA treatment did not alter
PLoS ONE | www.plosone.org 1 November 2010 | Volume 5 | Issue 11 | e13858intrahepatic triglyceride content. However, the baseline intrahe-
patic triglyceride content of the subjects in TUDCA treatment
group was only modestly increased (8.2%). Therefore, it remains
inconclusive whether oral administration of TUDCA reveals similar
effects to parenteral administration in terms of improving hepatic
steatosis. Since orally administrated TUDCA is absorbed via active
transport in the terminal ileum and undergoes a significant hepatic
first pass effect and enterohepatic circulation [23,24], the working
mechanism of orally administrated TUDCA may be different from
that of intraperitoneally injected TUDCA [21].
We hereby investigated the effect of oral TUDCA treatment on
hepatic steatosis and gene expression in ob/ob mice. To figure out
the mechanism of action of TUDCA on hepatic steatosis, we
systematically analyzed the microarray data. First, we verified the
relevance of differentially expressed genes (DEGs) based on the
preexisting literature. Second, we analyzed the expression of the
genes regulating each component of lipid homeostasis (i.e., de novo
lipogenesis, uptake, oxidation, and export). Third, we conducted
gene enrichment analysis using Gene Ontology (GO) to identify
the significantly altered functional groups of DEGs. Lastly, we
adopted pathway analysis to elucidate the collective behavior of
DEGs, which provides complementary information to conven-
tional single gene-based analysis [25].
Materials and Methods
Animal experiments
The study protocol was approved by the Institutional Animal
Care and Use Committee of Seoul National University Hospital.
Six-week-old male ob/ob mice (C57BL/6J-ob/ob) and their
control littermates (C57BL/6J) were purchased from Shizuoka
Laboratory Center (Shizuoka, Japan). The ob/ob mice were given
TUDCA (Tokyo Tanabe, Tokyo, Japan) at a dose of 500 mg/kg
twice a day (8:00 AM and 8:00 PM) by gastric gavage for 3 weeks
(OB-TUDCA group, n=6). Given that the oral bioavailability of
TUDCA is approximately 65% [23], we doubled the dose of
TUDCA that used in intraperitoneal injection [21]. We
administered the same volume of tap water to control ob/ob
mice (OB-control group, n=6) and normal control C57BL/6J
mice (N-control group, n=6) twice a day by gastric gavage for 3
weeks. Mice were fed a normal chow diet (Purina LabDiet, St
Louis, MO, USA) ad libitum. Body weight and fed-state plasma
glucose levels were monitored during the study period. The serum
levels of aspartate aminotransferase (AST) and alanine amino-
transferase (ALT) were enzymatically measured using an autoan-
alyzer (ADVIA 1650, Siemens Medical Solutions Diagnostics,
Tarrytown, NY, USA).
At week 3, intraperitoneal glucose tolerance test (IPGTT) and
insulin tolerance test (ITT) were performed according to standard
methods. Briefly, for IPGTT, the mice were fasted overnight for
12 hours and glucose (0.5 g/kg) was intraperitoneally adminis-
tered at 9 AM. For ITT, the mice were fasted for 6 hours from 8
AM, when drug or vehicle was administered by gavage, and then
insulin (2 IU/kg) was intraperitoneally injected. Blood glucose
levels were measured using a hand-held glucometer (One Touch
Ultra, LifeScan, Milpitas, CA, USA).
Histomorphometric analysis and markers of oxidative
stress and ER stress
The mice were killed after an 8 hour fasting. The livers were
immediately retrieved and fixed in 10% neutral buffered formalin
for 24 hours or kept freshly frozen. The formalin fixed liver tissues
were embedded in paraffin. We performed hematoxylin and eosin
(H&E) staining on the paraffin embedded liver sections (4 mm
thickness) and oil red O staining on fresh frozen liver sections
(10 mm thickness). Oil red O stained liver sections were examined
under a light microscope (Olympus BX 50, Tokyo, Japan) at 1006
magnification, and the images were analyzed by Image J software
(National Institutes of Health, Bethesda, MD, USA). The hepatic
lipid content is presented as the percentage of oil red O stained
area per total liver parenchymal area in a given section. Markers
for ER stress were analyzed by Western blotting and reverse
transcription PCR (detailed methods are shown in Text S1). To
assess oxidative stress in the liver, we stained 4-hydroxy-2-nonenal
(4-HNE), a marker of lipid peroxidation, with a mouse anti-4-
HNE antibody (Abcam Inc., Cambridge, MA), and measured the
brown color intensity of 20 different regions with Image J.
Statistics
All data except the microarray results are presented as the mean
6 S.E.M. Using a commercial software (Prism 5.0, GraphPad,
San Diego, CA, USA), we performed t-test, Kruskal-Wallis test,
and Dunn’s multiple comparison test, where appropriate. A
P,0.05 was considered to be statistically significant.
Microarray
Isolation of total RNA from the liver tissue was performed using
the RNeasy Micro Kit (Qiagen, Valencia, CA, USA) according to
the manufacturer’s instructions. Probes for the GeneChipH Mouse
Gene 1.0 ST Array (Affymetrix, Santa Clara, CA, USA) were
prepared and hybridized using the GeneChip Whole Transcript
Sense Target Labeling Assay (Affymetrix) and scanned according
to the manufacturer’s instructions (Scanner 3000 7G, Affymetrix).
Methods for DEG selection and GO enrichment analysis are
shown in Text S1.
Identification of altered pathways
To interpret genome-wide mRNA expression profiles based on
biological pathways, we integrated mRNA expression data with
the well-documented 218 biological pathways downloaded from
the Kyoto Encyclopedia of Genes and Genomes (KEGG) database
as of November, 2008 [26]. We defined an average fold-change of
expression value of E(Mi) as an indicator of expression changes in
biological processes. For a pathway map Mi containing a gene set
S={g 1,g 2,… ,g k}, the score of the average differentially
expressed level is calculated as follows:
E(Mi)~
1
k
X
j[Mi
log2(Fj)
A high E(Mi) score indicates that a pathway map Mi is
differentially expressed. The statistic Fj indicates the fold-change
in expression of gene j between two experimental conditions. To
identify the differentially expressed pathways, we calculated the P-
values representing significant expression changes of identified
pathways. We applied a nonparametric permutation test, which
estimates the distribution of the statistic E(Mi) using the
permutations of genes or sample labels to compute the P-values.
We randomly permutated the expression ratio of genes 10,000
times to obtain the null distribution of E(Mi) for each pathway
map Mi assuming a Gaussian distribution.
Ranking relevant genes affected by oral TUDCA
administration using a PubMed keywords search
To verify the biological relevance of the DEGs, we adopted a
gene prioritization method based on PubMed database [27]. As of
Oral TUDCA Treatment
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keywords: ‘fat and liver’, ‘lipid and liver’, ‘triglyceride and liver’, or
‘fatty liver’. Then, we applied the following scoring function to
calculate the evidence scores (ES) for keyword hits:
ES(i)~
P
j
Nj(i)
N(i)za
where ES(i) is a combined score of the co-citation number of genes i
with keywords j. N(i) is the total number of papers related to the gene
i. Nj(i) indicates the number of papers detected by both gene i and
keyword j. We used a pseudo-count a of 10 to account important
genes that have more citations. We confirmed that the top ranked
genes from this method are related to lipid metabolism by
conducting gene enrichment analysis with the BiNGO plugin [28].
Results
Effect of TUDCA on hepatic steatosis and glucose
homeostasis
Oral TUDCA treatment markedly improved hepatic steatosis in
ob/ob mice as shown by H&E staining (Figure 1A). The oil red O
stained area approximately exhibited a 2-fold reduction in the OB-
TUDCA group as compared to the OB-control group
(21.1610.4% vs. 44.265.8%, P,0.05) (Figure 1A and 1B).
TUDCA treatment decreased serum ALT and AST levels in the
OB-TUDCA group as compared to the OB-control group
(Figure 1C and 1D). Serum triglyceride levels were not significantly
different between groups (N-control, 5667.7 mg/dl; OB-control,
80.0631.5 mg/dl; OB-TUDCA, 69.3613.1 mg/dl, P=0.205).
The 4-HNE staining was much stronger in the liver of OB-control
group than N-control group, which was markedly diminished by
TUDCA treatment (Figure 2). There were no differences in
expression of the ER stress markers, phosphorylated eIF2a levels
Figure 1. Effects of oral TUDCA treatment on hepatic steatosis in ob/ob mice. (A) H&E and oil red O staining of the liver shows a marked
improvement of steatosis. Scale bars indicate 200 mm. (B) Quantified fat content in oil red O stained liver sections was lower in the OB-TUDCA group
as compared to the OB-control group. (C, D) Serum ALT and AST levels tended to be lower in the OB-TUDCA group as compared to the OB-control
group. In panels B, C and D, * denotes P,0.05 compared to the N-control. P-values were calculated using the Kruskal-Wallis test and Dunn’s multiple
comparison test.
doi:10.1371/journal.pone.0013858.g001
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treatment groups. Comparing the OB-TUDCA group with the
OB-control group, there were no significant differences in the fed-
state glucose levels (Figure 3C), glucose tolerance assessed by
IPGTT (Figure 3D), and insulin sensitivity assessed by ITT
(Figure 3E) during the study period. In addition, the body weight
at day 21 was similar between the OB-control and OB-TUDCA
groups (39.661.5 g vs. 36.260.8 g, respectively; P.0.05).
Figure 2. Effects of oral TUDCA treatment on lipid peroxidation. (A) The 4-HNE staining of the liver shows that lipid peroxidation is increased
in ob/ob mice, which is reduced by TUDCA treatment. Scale bars in the top and bottom images indicate 200 mm and 800 mm, respectively.
(B) Quantification of the intensity of 4-HNE staining. * denotes P,0.05 compared to the N-control, and # denotes P,0.05 compared to OB-control.
doi:10.1371/journal.pone.0013858.g002
Figure 3. Effects of oral TUDCA treatment on ER stress and glucose homeostasis in ob/ob mice. (A) Phosphorylated eIF2a expression
levels are similar among groups. (B) Alternative splicing of Xbp1 was not detected in any of the three groups. The mRNAs isolated from thapsigargin-
treated 3T3 L1 cells were used as controls. (C–E) There was no difference in fed-state blood glucose levels (C), glucose tolerance assessed by IPGTT
(D), and insulin sensitivity assessed by ITT (E) between the OB-control and OB-TUDCA groups. Symbols and error bars represent means and SEM,
respectively. (N), N-control; (#), OB-control; and (&), OB-TUDCA mice.
doi:10.1371/journal.pone.0013858.g003
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To examine the effect of oral TUDCA treatment on hepatic
gene expression, we compared gene expression profiles of the liver
tissue isolated from OB-control and OB-TUDCA mice. First, we
assessed the reproducibility of the experiments by comparing the
log2 signal intensities of microarray data (Figure S1). Scatter plots
of log2 intensities from paired experiments showed a high level of
agreement between the samples (correlation coefficient r.0.98).
Next, we systematically analyzed the microarray data using
various approaches depicted in Figure 4A. We identified 357
DEGs (1,199 significantly altered probes) showing high overlap in
terms of both fold-change and SAM analyses (Figure 4B, Table
S1). In the OB-TUDCA group, 334 of 357 DEGs were down-
regulated (Table S2). Then, we prioritized the DEGs using
evidence scores (ES) as described in Materials and Methods. We
confirmed that the genes with high ES were enriched with the
Figure 4. Changes in hepatic gene expression in OB-control and OB-TUDCA groups. (A) Flowchart of DEG selection and relevant gene
search. DEGs were selected using SAM and fold-change analysis. The relevant genes were selected using a PubMed database search. (B) The
expression matrix shows the relative expression levels of DEGs for each condition. Each column of the matrix represents three experimental
conditions: N-control, OB-control, and OB-TUDCA groups. Each row of the matrix represents relative expression data that were gene-wise normalized.
Hierarchical clustering was conducted using the following parameters: Pearson correlation and single linkage method.
doi:10.1371/journal.pone.0013858.g004
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P,10
210). Among the total DEGs, 34 genes were identified as
relevant genes (Figure 4B, Table S4; hypergeometric test, P,10
29)
and revealed three distinct patterns: (i) over-expressed only in the
OB-control group, (ii) over-expressed only in the OB-TUDCA
group, (iii) down-regulated only in the OB-TUDCA group
(Figure 4B). In addition, we validated our microarray data by
measuring mRNA levels of representative genes (Scd2, Srebf1,
Lpin1, Pparg, Cyp7a1, and Abcb11) using quantitative real time-PCR
(Figure S2 and S3).
Regulation of hepatic lipid homeostasis
To examine which component of lipid homeostasis was altered
by TUDCA treatment, we categorized the genes involved in lipid
metabolism into four groups (i.e., de novo lipogenesis, lipid uptake,
lipid export, and lipid oxidation) based on the KEGG pathway
and manual curation analyses. As shown in Figure 5A, the de novo
lipogenesis group comprises of the majority of DEGs (hypergeo-
metric test, P,10
23). Expression levels of genes for fatty acid
synthesis (e.g., Acaca, Acacb, Acly, Gpam, Fasn, Me1, Pklr, and Thrsp)
were up-regulated in ob/ob mice but down-regulated with
TUDCA treatment (Figure 5B). Moreover, the fatty acid
elongation and desaturation enzymes (e.g., Scd2, Elovl6, Elovl5,
Fads2, and Elovl1) showed similar expression patterns to the fatty
acid synthesis enzymes (Figure 5B). In contrast, the expression
levels of the genes regulating lipid uptake were generally up-
regulated in both OB-control and OB-TUDCA groups. The key
lipid uptake genes (e.g., Cd36, Mgl1, and Pltp) were increased in the
OB-control mice and their expression levels were not altered with
TUDCA treatment (Figure 5C). We examined the expression of
genes regulating the metabolism of very low density lipoprotein
(VLDL), a major pathway regulating hepatic triglyceride export;
Apoa4 was highly up-regulated in ob/ob mice but its expression
was not affected by TUDCA treatment. Other VLDL-related
genes, including Apob, Apoe, Apoc3, and Mttp, showed comparable
mRNA expression levels among the three groups (Figure 5D). The
expression levels of fatty acid oxidation-related genes were slightly
up-regulated in OB-control mice and their expression levels were
not significantly different with TUDCA treatment except for Aacs,
which showed a further increase with TUDCA treatment
(Figure 5E).
Biological pathways affected by TUDCA treatment
In general, genes cooperate with other genes as some parts of
pathways that regulate specific biological processes. These
associations are of particular importance for relating an altered
phenotype with drug treatment at molecular level. To examine the
gene expression changes in pathways other than lipid metabolism,
we analyzed altered biological pathways in response to TUDCA
treatment. We focused on the pathways that were enriched with
up- or down-regulated genes and identified 29 differentially
expressed pathways (6 up-regulated and 23 down-regulated)
(Figure 6A, Table S5). Down-regulated pathways in the OB-
TUDCA group as compared to the OB-control group included
fatty acid biosynthesis, fatty acid metabolism, glutathione
metabolism, sulfur metabolism, xenobiotic metabolism, and amino
acid metabolism. Most of the altered pathways in this network are
extensively connected by common metabolites or genes and
display similar expression patterns (Figure 6A). Ribosome,
inflammatory responses, and cell signaling pathways were up-
regulated. Most differentially expressed pathways (DEPs) showed
opposite directions of regulation (Figure 6B). These results are
supported by GO analysis of biological processes involving the
identified DEPs (Table 1).
Discussion
Although the prevalence of NAFLD is alarmingly high, only
lifestyle modifications to reduce body weight are generally
recommended to treat NAFLD [1,2,3]. In this regard, weight-
lowering drugs, such as orlistat and sibutramine, were reported to
reduce hepatic steatosis and/or serum liver enzyme levels [29,30].
However, there are no available drugs that have been proven to
effectively and safely treat hepatic steatosis independent of weight
loss [1]. Thiazolidinediones increase insulin sensitivity and
decrease hepatic steatosis and inflammation in humans [11], but
they have several side effects including weight gain, heart failure,
and increased fracture risk [31]. In the current study, we show that
oral TUDCA treatment effectively improves fatty liver disease in
ob/ob mice independent of weight loss; this improvement is
accompanied by alterations in gene expression, biological
processes, and metabolic pathways in the liver.
Although TUDCA is known as a chemical chaperone against
ER stress [21], orally administered TUDCA did not alter ER
stress markers in the present study. Furthermore, the mRNA levels
of ER stress-related genes, such as Atf4, Grp78, Trb3 and Edem,
were comparable among the three treatment groups (Figure S4).
Instead, the expression of glutathione S-transferase (Gst) genes
(i.e., Gsta1, Gsta2, Gsta4, Gstm1, Gstm2, Gstm3, and Gstm4), which
are known to increase their expression under oxidative stress [32],
were up-regulated in the OB-control group and down-regulated
upon TUDCA treatment (Figure S4) implying that oral TUDCA
treatment may decrease oxidative stress in the liver. In this regard,
TUDCA is known to have antioxidant property that curtails the
production of reactive oxygen species [33,34]. Indeed, we noticed
the 4-HNE staining, a marker of lipid peroxidation, was increased
in OB-control group compared to N-control group, which was
markedly decreased with TUDCA treatment. Of interest, a recent
randomized controlled trial revealed that vitamin E, a represen-
tative antioxidant available in clinical practice, improves not only
hepatic steatosis but also NASH in humans [35]. It is also
noteworthy that ER stress does not necessarily accompany fatty
liver disease in several independent studies (Table S6). Therefore,
we speculate that orally administered TUDCA might improve
hepatic steatosis by reducing oxidative stress rather than alleviating
ER stress.
Hepatic steatosis results from an imbalance in lipid homeostasis
in the liver, where lipid uptake or de novo lipogenesis outweighs
lipid oxidation or export. The fatty acids in hepatic triglycerides
are derived from dietary sources in the form of chylomicron
remnants, free fatty acids released from adipose tissue, or from de
novo lipogenesis [36]. De novo lipogenesis accounts for less than 5%
in healthy subjects during the postprandial period, while it is
known to significantly increase up to 15% in subjects with fatty
liver disease [37,38]. Therefore, enhanced de novo lipogenesis is
regarded to be a major abnormality of hepatic lipid metabolism in
subjects with NAFLD. In mouse models, the knockout of key
enzymes involved in lipid synthesis (e.g., Acc, Elovl6, Scd1, Gpat,o r
Dgat) reduces hepatic steatosis (reviewed in [39]). Taken together,
therapeutic agents targeting a reduction in hepatic de novo
lipogenesis would be suitable to treat NAFLD patients. In this
study, TUDCA markedly reduced hepatic fat content, which was
accompanied by a reduction in the expression of Srebf1 and its
down-stream target genes (e.g., Scd2, Elovl6, and Acaca), which is
crucial in de novo lipogenesis, while other groups of genes involved
in lipid uptake, oxidation, and export were not altered (Figure 5).
Since Srebf1 is known to link oxidative stress to hepatic steatosis
[40,41], alleviation of oxidative stress by TUDCA likely decreases
the expression of Srebf1 and subsequently reduces de novo
Oral TUDCA Treatment
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Pparg, which is a critical transcription factor in development of
hepatic steatosis in ob/ob mice [42], and its direct target genes
(e.g., Cidec, Cd36, and Ucp2), suggesting that the TUDCA effect in
improving hepatic steatosis is Pparg-independent (Figure S5).
Collectively, TUDCA is a promising drug to treat NAFLD, which
down-regulates the genes involved in de novo lipogenesis.
Although TUDCA substantially reduced hepatic fat content in
this study, we could not find any evidence of improved glucose
homeostasis. The increased triglyceride content in the liver, the
hallmark of NAFLD, is strongly associated with the development
of insulin resistance [43,44,45]. Although there was no difference
in systemic insulin sensitivity assessed by ITT in this study, we
cannot exclude the possibility of altered hepatic insulin sensitivity
with TUDCA treatment. Our finding is consistent with a recent
study in obese human subjects, which demonstrated that 4-week
oral TUDCA treatment improved insulin sensitivity in the liver
and muscle but did not improve systemic insulin sensitivity and
glucose levels [22].
There are a few limitations in this study. (1) Although we
administered oral TUDCA twice as much as the dose used in
intraperitoneal injection, we could not reproduce improved
glucose homeostasis found by Ozcan et al. [21]. In this regard,
we cannot rule out the possibility that the actual tissue
concentration of TUDCA with oral route of administration was
lower than that with intraperitoneal administration. We also found
that the mRNA expression levels of Abcb11, a bile acid transporter
[46], and Cyp7a1, a bile acid metabolizing enzyme [47], were
lower in OB-control group than N-control and were further
reduced with TUDCA treatment, which might affect plasma and
tissue concentration of TUDCA or other bile acids (Figure S2 and
S3). (2) Since the ob/ob mouse is genetically lacking leptin, it may
not be an optimal model for common NAFLD in humans. For
example, it has been reported that ob/ob mice are resistant to the
development of necroinflammation and fibrosis [48]. Hence, our
findings need to be confirmed in other animal models such as
dietary models and in human subjects. (3) The human equivalent
dose corresponding 1,000 mg/kg in mice is ,80 mg/kg (assuming
60 kg of body weight), which is a higher dose compared to the
usual dose of UDCA for primary sclerosing cholangitis
(20,30 mg/kg/day) [49]. Therefore, the safety and efficacy of
higher doses of TUDCA should be determined in humans.
In order to identify relevant DEGs and to grasp the dynamic
behavior of genes responsible for the recovery of hepatic steatosis
by oral TUDCA treatment, we adopted systems biology tools (e.g.,
a PubMed keywords search and pathway analysis). Using PubMed
keywords search, we could validate the selected DEGs based on
the preexisting literature dealing with hepatic lipid metabolism.
Furthermore, pathway analysis provided us insights to understand
the collective behavior of DEGs. We conclude that oral TUDCA
administration decreased hepatic lipid content in ob/ob mice by
cooperative regulation of genes involved in multiple metabolic
pathways, particularly by decreasing the expression of genes
regulating de novo lipogenesis.
Figure 6. Relationships between altered pathways in the OB-TUDCA group. (A) Abstract view of the pathway-pathway network; it shows
the relationship among the pathways by connecting common genes. The colors of triangles represent the average changes in expression of genes
involved in the pathway. (B) Average log2 fold-change expression pattern of DEPs in N-control vs. OB-control groups and OB-TUDCA vs. OB-control
groups. Hierarchical clustering was conducted using the following parameters: Pearson correlation and single linkage method.
doi:10.1371/journal.pone.0013858.g006
Figure 5. Alteration of gene expression in lipid flux regulating groups. (A) The percentages of included DEGs in each group and its
statistical significance. (B–E) Expression changes of genes involved in de novo lipogenesis, lipid uptake, export, and oxidation.
doi:10.1371/journal.pone.0013858.g005
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Figure S1 Correlation of log2 intensities within the same groups.
Scatter plots of log2 intensities from a pair of experiments within
(A) N-control, (B) OB-control, and (C) OB-TUDCA groups. The
coefficient of correlation r value is given for each pair.
Found at: doi:10.1371/journal.pone.0013858.s001 (0.85 MB TIF)
Figure S2 mRNA expression of Scd2, Srebf1, Lpin1, Pparg,
Cyp7a1, and Abcb11. The levels of gene expression were
measured by quantitative RT PCR. * denotes P,0.05 compared
to N-control, and # denotes P,0.05 compared to OB-control.
Found at: doi:10.1371/journal.pone.0013858.s002 (0.44 MB TIF)
Figure S3 mRNA expression of Scd2, Srebf1, Lpin1, Pparg,
Cyp7a1, and Abcb11. mRNA expression levels measured by
microarray experiments are depicted. * denotes P,0.05 compared
to N-control, and # denotes P,0.05 compared to OB-control.
Found at: doi:10.1371/journal.pone.0013858.s003 (0.20 MB TIF)
Figure S4 Alterations in mRNA expression levels of genes
related to ER stress and oxidative stress.
Found at: doi:10.1371/journal.pone.0013858.s004 (0.20 MB TIF)
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